EUVIMEDEUVIMED entdecken
Crossref

Acute Musculoskeletal Pain Syndrome in Acute Promyelocytic Leukemia Patients During Induction Therapy: A Preliminary Report

Michal J Kubiak, Shashank Madarapu, Shawn Michael Doss, Matthew Gold, Vamsi Kota iD, Locke Bryan, Anand P Jillella

Acta Haematologica · 14.11.2026

DOI: 10.1159/aha/abkag018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 14.11.2026. Verfasst von Michal J Kubiak und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute Promyelocytic Leukemia (APL) is a highly curable subtype of Acute Myelogenous Leukemia (AML) with survival rates exceeding 90% following therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Despite these advancements, induction complications, such as bleeding and differentiation syndrome (DS), remain contributors to morbidity and early mortality.

Objectives

This preliminary retrospective study aims to characterize an underreported musculoskeletal (MSK) pain syndrome during induction therapy.

Methods

We reviewed medical records of 52 APL patients who underwent induction therapy at our leukemia center between March 2014 and November 2025. Acute MSK pain events were defined as MSK pain, requiring medical intervention, and excluding other etiologies.

Results

Eleven patients (21.2%) experienced acute MSK pain events, all with a presenting white blood cell count ≤10 × 10³/µL (non-high-risk); the pain was predominantly bone pain. The median time to MSK pain onset was 11 days post-induction initiation. Management included temporary interruption of differentiation agents, steroid initiation, aggressive leukoreduction, and pain medications. All MSK pain episodes resolved following these interventions, and no patients developed DS or experienced induction-related mortality.

Conclusions

This study highlights MSK pain syndrome in a subset of APL patients during induction therapy, suggesting it may represent an inflammatory complication. Early recognition and intervention in our experience have resulted in resolution of the symptoms. Given the preliminary nature and small sample size, further observation is warranted to elucidate the pathophysiology and implications of MSK pain in APL treatment.

Autor:innen und Institutionen

ORCID-Profile: Vamsi Kota

Zitieren

APA

Kubiak, M. J., Madarapu, S., Doss, S. M., Gold, M., Kota, V., Bryan, L., & Jillella, A. P. (2026). Acute Musculoskeletal Pain Syndrome in Acute Promyelocytic Leukemia Patients During Induction Therapy: A Preliminary Report. Acta Haematologica. https://doi.org/10.1159/aha/abkag018

Vancouver

Kubiak MJ, Madarapu S, Doss SM, Gold M, Kota V, Bryan L, et al. Acute Musculoskeletal Pain Syndrome in Acute Promyelocytic Leukemia Patients During Induction Therapy: A Preliminary Report. Acta Haematologica. 2026. doi:10.1159/aha/abkag018

BibTeX
@article{Kubiak2026,
  author = {Kubiak, Michal J and Madarapu, Shashank and Doss, Shawn Michael and Gold, Matthew and Kota, Vamsi and Bryan, Locke and Jillella, Anand P},
  title = {Acute Musculoskeletal Pain Syndrome in Acute Promyelocytic Leukemia Patients During Induction Therapy: A Preliminary Report},
  journal = {Acta Haematologica},
  year = {2026},
  doi = {10.1159/aha/abkag018}
}
Kostenlos starten →